Patches tries to smother Linda in loose fur.
Okay, enough pussy-footing
around. We need to tackle PARP
Inhibitors head on, wrestle them to the earth, and stomp on them. What, you don’t have any idea what a PARP
Inhibitor is, and furthermore you don’t give a damn? Shame on you, and who cares about you,
anyway? I’m mainly writing this thing in
the fervent hope that “PARP Inhibitor”, which I have looked up at least a dozen
times, finally will stick in my head.”
First, definitions: PARP code for “poly ADP ribose
polymerase”. Does that help? Of course not. “poly you understand. Polymerase is something that causes
rapid duplication of a biochemical thing to occur. The term "ribose" refers to the structure of the molecule and is of no earthly significance here.
It turns out that ADP stands for adenosine diphosphate. ADP is essential in the transfer of energy
within cells, and so PARP refers to the mass production of something that is
essential to life. Add “Inhibitor” and
you are referring to something that Inhibits
life. Now, why in heaven’s name
would you want to do that?
Well, cancer cells are “life”, so we should
inhibit the hell out of them. The problem, of course, is to target cancer
cells without shutting down all the rest of the organism at the same time. Part of the answer lies in the fact that
cancer cells divide and multiply much faster than normal cells, and thus toss
up more potentially fatal DNA-replication errors to “inhibit”.
Also, many kinds of cancers have defective “repair” proteins, such as
the well-known BRCA1 and 2 that are so important in ovarian and breast cancer,
hence can’t fix the damage, whereas normal cells with normal BRCA can. Ah, but something is missing so far. The protein PARP1 fixes single-strand breaks
in DNA, and if these breaks are not repaired double-stranded errors can ensue
WHICH, in the absence of functional repair proteins, will cause the cell to croak.
It appears that the complete activity
of PARP proteins is not fully understood.
Many trials are underway. Several
drugs already have been tested – and failed.
Clovis Oncology has three PARP Inhibitor drugs in clinical trial right
now, and other drug companies are in the hunt.
Can we allow ourselves to be optimistic?
Well, maybe.